Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

被引：2
|
作者：
Owen, Dwight H.
Otterson, Gregory A.
机构：
[1] Ohio State Univ, Wexner Med Ctr, Div Med Oncol, Columbus, OH 43210 USA
[2] James Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
CELL LUNG-CANCER; NIVOLUMAB; PNEUMONITIS; DOCETAXEL; PROFILE; PEMBROLIZUMAB; CHEMOTHERAPY;
D O I：
10.21037/jtd.2018.09.102
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S4069 / S4072
页数：4
相关论文
共 50 条
  • [21] Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis
    Chakravarti, Nitin
    Prieto, Victor G.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 743 - 751
  • [22] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [23] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [24] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [25] Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
    Mori, Keiichiro
    Pradere, Benjamin
    Quhal, Fahad
    Katayama, Satoshi
    Mostafaei, Hadi
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    D'Andrea, David
    Egawa, Shin
    Bensalah, Karim
    Schmidinger, Manuela
    Powles, Thomas
    Shariat, Shahrokh F.
    CANCER TREATMENT REVIEWS, 2021, 99
  • [26] Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis
    Yanaba, Koichi
    Hayashi, Mitsuha
    Yoshihara, Yuki
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2016, 43 (08): : 954 - 957
  • [27] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [28] Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
    Wang, Yiming
    Ma, Rena
    Liu, Fang
    Lee, Seul A.
    Zhang, Li
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [29] Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
    Zhou, Tingting
    Xu, Di
    Tang, Bufu
    Ren, Yanling
    Han, Yiru
    Liang, Gege
    Wang, Jing
    Wang, Ling
    ANTI-CANCER DRUGS, 2018, 29 (09) : 904 - 910
  • [30] Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
    Lei Liu
    Pengpeng Lan
    Guiping Wu
    Xiaojie Zhu
    Hongfeng Shi
    Yan Li
    Ruili Li
    Ling Zhao
    Juan Xu
    Min Xu
    Scientific Reports, 14 (1)
12345